International Journal of Drug Delivery Technology
Volume 14, Issue 3

Formulation and Evaluation of Sustained Release Dosage Form of Venlafaxine Hydrochloride for Enhanced Treatment of Neurodisorders

Nilesh Sureshrao Mhaske, S Sathesh Kumar*

Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, and Advanced Studies (VISTAS), Chennai, India. 

Received: 24th March, 2024; Revised: 19th June, 2024; Accepted: 09th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

In the present study, we have designed and developed a sustained-release tablet formulation of Venlafaxine Hydrochloride. The optimized formulation was then subjected to various evaluation parameters. The formulation of venlafaxine hydrochloride sustained release tablets with a dosage of 500 mg included the utilization of several hydrophilic polymers, including jackfruit mucilage, HPMC K4, and PVPK30, as release retardants. This was done to extend the duration of drug release to 12 hours. The formulation features, including pre-compression and post-compression investigations, were conducted individually according to established protocols. The tablets were determined to be compliant in terms of weight uniformity, hardness, thickness, diameter, friability, and drug content. Separate in-vitro dissolution studies were done for both tablets. The venlafaxine hydrochloride SR formulation F18 was optimized to provide the desired release profile for up to 12 hours. The Venlafaxine Hydrochloride SR formulation was optimized and exhibited zero-order release kinetics. The stability studies conducted under accelerated conditions at a temperature of 40 ± 2°C and a relative humidity of 75 ± 5% yielded good results. The study indicated that the sustained release administration of Venlafaxine HCl is potentially efficacious. It reduces the frequency at which the patient has to take medication and improves patient adherence. Our objective is to conduct in-vivo pharmacokinetic studies of the formulation to verify the drug’s entry into the systemic circulation.

Keywords: Venlafaxine HCl, Sustained release, tablet, in-vitro, release kinetics. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.33

How to cite this article: Mhaske NS, Kumar SS. Formulation and Evaluation of Sustained Release Dosage Form of Venlafaxine Hydrochloride for Enhanced Treatment of Neurodisorders. International Journal of Drug Delivery Technology. 2024;14(3):1495-1504.

REFERENCES

  1. Patel H, Patel MM. Formulation and Evaluation of Controlled Porosity Osmotic Drug Delivery System of Carvedilol J Pharm Sci Biosci Res. 2012;2(2):77–82.
  2. Bose S, Kaur A, Sharma a Review on Advances of Sustained Release Drug Delivery System. Int Res J Pharm. 2013;4(6):1–5. Available from: http://www.jpsbr.org/index_htm_files/8%20 JPSBR%2012078.pdf
  3. Bundela Y, Agrawal D, Bhaduka An overview on fundamentals of immediate release drug delivery system. J Appl Pharm Res. 2022;10(3):01–4. Available from: https://doi.org/10.18231/j. joapr.2022.10.3.1.4
  4. Jain A, Chauhan R, Singh S, Kulkarni S, Jain Optimization of coating material for sustained release venlafaxine hydrochloride tablet. Int J Life Sci Pharma Res. 2015;5(3):P1–12. Available from: https://www.ijlpr.com/index.php/journal/article/view/437
  5. Mahesh PG, Jeganath S. Formulation and evaluation of venlafaxine hydrochloride sustained release matrix Asian J Pharm Clin Res. 2018;11(Special Issue 4):170–4. Available from: https://www.ijlpr.com/index.php/journal/article/view/437
  6. Butani SB. Development and Optimization of Venlafaxine Hydrochloride Sustained Release Triple Layer Tablets Adopting Quality by Design Approach. Pharmacol & Pharm. 2013;04(03):9–16. DOI: 10.4236/pp.2013.43A002
  7. He Y, Yu Y, Zhang L, Fang Z, Wu Z. Pharmacokinetics and bioequivalence of Venlafaxine hydrochloride sustained release tablets in Beagle Drug Eval Res. 2019;42(7):1314–7. DOI: 10.7501/j.issn.1674-6376.2019.07.010
  8. Bhandwalkar MJ, Avachat AM. Thermoreversible nasal in situ gel of venlafaxine hydrochloride: Formulation, characterization, and pharmacodynamic evaluation. AAPS PharmSciTech. 2013;14(1):101–10. DOI: 1208/s12249-012-9893-1
  9. Schmitt J, Flemming HC. FTIR-spectroscopy in microbial and material analysis. Int Biodeterior Biodegrad. 1998;41(1):1–11. DOI: 10.1016/S0964-8305(98)80002-4
  10. Spectroscopy of Organic Compounds UV and IR. Dept Chem. 2006;1–36. ISBN: 81-224-1543-1
  11. Wisudyaningsih B, Setyawan D, Co-crystallization of quercetin and isonicotinamide using solvent evaporation method. Trop J Pharm Res. 2019;18(4):672–702. DOI: 10.4314/ tjpr.v18i4.3
  12. Chandira RM, Venkataeswarlu BS, Kumudhavalli MV, Debjitbhowmik, Jayakar B. Formulation and evaluation of mouth dissolving tablets of the etoricoxib. Pak J Pharm Sci. 2010;23(2):178–81. Available from: https://pubmed.ncbi.nlm. gov/20363696/
  13. Khan GM, Jiabi Z. Formulation and in vitro evaluation of ibuprofen-carbopol(®) 974P-NF controlled release matrix tablets III: Influence of co-excipients on release rate of the J Control Release. 1998;54(2):185–90. DOI: 10.1016/S0168- 3659(97)00225-3
  14. Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid Int J Pharm. 1998;166(2):177–DOI: 10.1016/S0378-5173(98)00046-5
  15. Jaipal A, Pandey MM, Charde SY, Raut PP, Prasanth KV, Prasad RG. Effect of HPMC and mannitol on drug release and bioadhesion behavior of buccal discs of buspirone hydrochloride: In-vitro and in-vivo pharmacokinetic studies. Saudi Pharm J. 2015;23(3):315–26. DOI: 1016/j.jsps.2014.11.012
  16. Singh C, Yashwant, Gupta Formulation and the Study of Finished Products Used for Anginal Disease. International Journal of Pharmaceutical Quality Assurance. 2022;13(4):385-DOI: 10.25258/ijpqa.13.4.07